

Long Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9597388/publications.pdf>

Version: 2024-02-01

25
papers

698
citations

758635

12
h-index

713013

21
g-index

26
all docs

26
docs citations

26
times ranked

158
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative analysis from multi-center studies identifies a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer. <i>EBioMedicine</i> , 2022, 75, 103750.	2.7	73
2	Clinical Significance and Immune Landscape of a Pyroptosis-Derived lncRNA Signature for Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 805291.	1.8	14
3	EGR1 and KLF4 as Diagnostic Markers for Abdominal Aortic Aneurysm and Associated With Immune Infiltration. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 781207.	1.1	7
4	Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. <i>Nature Communications</i> , 2022, 13, 816.	5.8	192
5	Integrated Analysis of Multi-Omics Alteration, Immune Profile, and Pharmacological Landscape of Pyroptosis-Derived lncRNA Pairs in Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 816153.	1.8	15
6	Development and Validation of Ischemic Events Related Signature After Carotid Endarterectomy. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 794608.	1.8	5
7	Exploring Key Genes to Construct a Diagnosis Model of Dilated Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 865096.	1.1	4
8	LINC00958: A promising long non-coding RNA related to cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113087.	2.5	8
9	TTN/OBSCN "DoubleHit" predicts favourable prognosis, "immune-hot" subtype and potentially better immunotherapeutic efficacy in colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3239-3251.	1.6	34
10	Development and validation of a robust immune-related risk signature for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e24683.	0.4	7
11	The Identification and Validation of Two Heterogenous Subtypes and a Risk Signature Based on Ferroptosis in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 619242.	1.3	48
12	Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 669694.	1.1	34
13	Establishment and experimental validation of an immune miRNA signature for assessing prognosis and immune landscape of patients with colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 6874-6886.	1.6	29
14	Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 682084.	1.6	29
15	CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: A pan-cancer analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7559-7574.	1.6	11
16	Clinical Significance and Inflammatory Landscape of a Novel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 702594.	2.2	36
17	Development and clinical validation of a novel six-gene signature for accurately predicting the recurrence risk of patients with stage II/III colorectal cancer. <i>Cancer Cell International</i> , 2021, 21, 359.	1.8	28
18	Comprehensive Molecular Analyses of a Six-Gene Signature for Predicting Late Recurrence of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 732447.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management. <i>Journal of Oncology</i> , 2021, 2021, 1-20.	0.6	26
20	Computational Recognition and Clinical Verification of TGF- β 2-Derived miRNA Signature With Potential Implications in Prognosis and Immunotherapy of Intrahepatic Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 757919.	1.3	22
21	Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 101, 108340.	1.7	23
22	Molecular Characterization and Clinical Relevance of ALDH2 in Human Cancers. <i>Frontiers in Medicine</i> , 2021, 8, 832605.	1.2	4
23	Somatic mutations in homologous recombination pathway predict favourable prognosis after immunotherapy across multiple cancer types. <i>Clinical and Translational Medicine</i> , 2021, 11, e619.	1.7	31
24	An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 766609.	1.6	9
25	ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1